Nalaganje...
ERCC1 Induction after Oxaliplatin Exposure May Depend on KRAS Mutational Status in Colorectal Cancer Cell Line: In Vitro Veritas
Introduction: Oxaliplatin (Oxa) is widely used in metastatic colorectal cancer (mCRC), but currently there are not valid predictors of response to this drug. In the control arms both of OPUS and PRIME studies Oxa seems more active in patients with mCRC with mutated (mt) KRAS than in those with wild...
Shranjeno v:
| izdano v: | J Cancer |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Ivyspring International Publisher
2015
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4278917/ https://ncbi.nlm.nih.gov/pubmed/25553091 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.10478 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|